October 2019 Question of the Month

Biosimilars have gotten off to a slow start in the marketplace. What change will most dramatically affect the adoption rate?

PBM Formulary and coverage decisions: 83%

New Legislation: 17%

HHS/CMS Policy Changes: 0%